We previously described a novel orally bioavailable CDK9 inhibitor, CDKI-73, and provided preclinical evidence for its utility as a targeted therapeutic agent for leukemia, ovarian cancer, colorectal cancer, and melanoma [20–25]. This evidence concerns the gene CDK9 and leukemia.